In compliance with current regulations, let us know which audience you belong to:
Our groundbreaking LM®LLLT technology represents a promising solution to slow down the progression of dAMD.
Photobiomodulation (PBM) is a light energy-based technology that stimulates cellular repair and regeneration, offering a promising avenue for dry AMD treatment, especially for AMD stages in the AREDS 3 and lower classifications.
LM® LLLT (PBM) is an established and non-invasive technology with thousand of published articles detailing its cellular mechanism and effects in a variety of medical conditions. Recently it has been proved to be effective to slow dAMD progression, safeguard vision, and enhance patients’ quality of life.
As age advances, AMD worsens due to an increase of Reactive Oxygen Species (ROS), damaging the retina. Mitochondria, the primary ROS source, are crucial. PBM targets mitochondrial dysfunction, boosting ATP and reducing oxidative stress, slowing dAMD progression and supporting retinal health.
The findings from our LightWave I study,recently published on Ophthalmology and Therapy1 journal, represent the first multi-center randomized controlled trial investigating PBM treatment in dAMD.
The results are exceptionally promising, demonstrating both the efficacy and safety of PBM in managing dAMD, and marking a significant breakthrough in the treatment of this challenging condition.
1 Borrelli, E., Coco, G., Pellegrini, M. et al. Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration. Ophthalmol Ther (2024).
Operators and patients can enjoy the unique benefits of LM® LLLT technology.